Want to see SE:ONCOZ full AI Analyst Report?
Top Page
OncoZenge AB
(ONCOZ)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr3.50
▼(-36.48% Downside)
Action:Reiterated
Date:10/13/26
The score is driven primarily by weak financial performance: substantial ongoing losses, heavy cash burn, and negative equity create high funding/solvency risk despite improving revenue. Technicals are mixed with the stock below key longer-term moving averages and negative MACD, while valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Revenue Growth
Revenue more than doubled year over year, indicating improving commercialization traction for the company’s oncology supportive-care products. Although growth starts from a small base, continued top-line expansion could strengthen operating leverage and provide a larger foundation for future investment.
Negative Factors
Persistent Operating Losses
The scale of operating and net losses remains far above current revenue, indicating that the company’s cost base is not yet supported by commercialization. Persistent losses can delay self-funded growth, require continued capital access, and limit the durability of earnings improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue more than doubled year over year, indicating improving commercialization traction for the company’s oncology supportive-care products. Although growth starts from a small base, continued top-line expansion could strengthen operating leverage and provide a larger foundation for future investment.
Read all positive factors
OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr100.31M
Dividend YieldN/A
Average Volume (3M)63.04K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth115.26%
EPS Growth-230.43%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.92
Shares Outstanding26,501,244
10 Day Avg. Volume62,061
30 Day Avg. Volume63,042
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.83
Revenue Forecast (FY)kr5.00M
OncoZenge AB Business Overview & Revenue Model
Company Description
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clin...
OncoZenge AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.84M | 2.66M | 1.00K | 3.00K | 0.00 | 0.00 |
| Gross Profit | 3.96M | -4.84M | 1.00K | 3.00K | 0.00 | 0.00 |
| EBITDA | -25.44M | -15.87M | -8.69M | 7.27M | 2.77M | -4.89M |
| Net Income | -26.18M | -15.94M | -8.69M | -15.90M | -46.65M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 11.73M | 15.34M | 11.43M | 20.34M | 36.89M | 85.23M |
| Cash, Cash Equivalents and Short-Term Investments | 749.00K | 3.71M | 3.86M | 12.63M | 29.14M | 51.22M |
| Total Debt | 7.50M | 7.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 17.03M | 15.92M | 1.48M | 1.70M | 2.92M | 4.90M |
| Stockholders Equity | -5.30M | -587.00K | 9.95M | 18.64M | 33.97M | 80.32M |
Cash Flow | ||||||
| Free Cash Flow | -10.73M | -13.06M | -8.76M | -17.08M | -22.08M | -10.12M |
| Operating Cash Flow | -23.79M | -13.06M | -8.76M | -17.08M | -22.08M | -4.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 570.00K | 0.00 | -5.36M |
| Financing Cash Flow | 22.98M | 12.91M | 0.00 | 0.00 | 0.00 | 51.34M |
OncoZenge AB Technical Analysis
Neutral
5.51
Price Trends
4.07
Negative
4.96
Negative
4.96
Negative
Market Momentum
-0.08
Negative
52.47
Neutral
72.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Neutral. The current price of 5.51 is above the 20-day moving average (MA) of 3.45, above the 50-day MA of 4.07, and above the 200-day MA of 4.96, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 52.47 is Neutral, neither overbought nor oversold. The STOCH value of 72.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ONCOZ.
OncoZenge AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr364.27M | 1.90 | 63.09% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr925.17M | -3.11 | ― | ― | 87.23% | 35.27% | |
48 Neutral | kr251.91M | -3.86 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr193.54M | -8.20 | -56.09% | ― | ― | 14.10% | |
44 Neutral | kr100.31M | -1.97 | -2775.09% | ― | 115.26% | -230.43% | |
43 Neutral | kr336.20M | -2.96 | -18.05% | ― | ― | 15.97% |
* Healthcare Sector Average
SE:ONCOZ
OncoZenge AB
3.65
-1.31
-26.47%
SE:ONCO
Oncopeptides AB
2.32
-2.57
-52.54%
SE:ISOFOL
Isofol Medical AB
0.82
0.06
8.61%
SE:ELIC
Elicera Therapeutics AB
2.94
-3.88
-56.89%
SE:IMMU
Immunicum AB
5.50
-0.10
-1.79%
SE:CANTA
Cantargia AB
1.29
-1.23
-48.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.